Description
Teoxane Teosyal® RHA 3 is a hyaluronic acid–based dermal filler developed using Teoxane’s proprietary Resilient Hyaluronic Acid (RHA®) technology. This formulation is designed to adapt to dynamic facial movements, maintaining structural integrity and elasticity in areas subject to repeated expression. RHA technology modifies the cross-linking process to preserve the natural HA chain length, supporting tissue integration and mechanical resilience under stress.
Teosyal® RHA 3 is classified as a resorbable dermal filler intended for the correction of moderate to marked facial wrinkles and folds, particularly in mobile facial zones. The product contains non-animal stabilised hyaluronic acid and includes lidocaine hydrochloride to improve patient comfort during injection. Its viscoelastic profile positions it between softer RHA formulations and higher projection fillers, offering balanced volumisation while preserving natural facial dynamics.
What Teosyal® RHA 3 Is Similar To
Teosyal® RHA 3 belongs to the category of resilient hyaluronic acid dermal fillers formulated for dynamic facial zones. Within the Teosyal RHA range, it sits between RHA 2 and RHA 4, offering a mid-range balance of flexibility and support. Compared with RHA 2, RHA 3 provides greater structural capacity for more pronounced folds, while remaining more adaptable than higher projection fillers.
In the wider market, it may be compared for orientation purposes with fillers such as Juvéderm® Volift or Restylane® Refyne, which are also designed to accommodate facial movement. Differences exist in cross-linking technologies, HA concentration, and rheological properties, which influence tissue behaviour and longevity. Teosyal® RHA 3 emphasises resilience under dynamic stress through its RHA® manufacturing process, whereas other fillers may prioritise lift or firmness.
This comparison is provided for clinical orientation only and does not imply interchangeability.
Treatment Areas / Indications
According to publicly available manufacturer information, Teosyal® RHA 3 is indicated for correction of facial wrinkles and folds in dynamic areas.
Specific treatment areas are not fully detailed in the publicly accessible IFU and are therefore described as:
-
Facial wrinkles and folds (general indication)
Detailed anatomical treatment areas not provided by manufacturer.
Usage / Administration (IFU-only section)
All administration parameters must follow the official Teoxane IFU.
-
Injection depth: not provided by manufacturer
-
Volume per injection point: not provided by manufacturer
-
Needle gauge: not provided by manufacturer
-
Frequency / number of sessions: not provided by manufacturer
-
Professional use: Teosyal® RHA 3 must be administered only by qualified medical professionals, under aseptic conditions, and in accordance with the official IFU.
Some practitioners apply specific techniques based on clinical experience; these are not included in the manufacturer’s official IFU.
Ingredient List
-
Cross-linked hyaluronic acid (non-animal origin)
-
Lidocaine hydrochloride – present (exact percentage not provided by manufacturer)
-
Phosphate buffer system
-
Water for injections
HA concentration: not provided by manufacturer
Presentation & Longevity
-
Packaging: 2 × 1.2 mL prefilled syringes
-
Sterility: sterile, single-use syringes
-
Shelf life: not provided by manufacturer
-
Treatment longevity: not provided by manufacturer
Longevity may vary depending on patient factors and treatment protocol, but no specific duration is stated in the official IFU.
Safety Notes / Contraindications
Based on manufacturer documentation and standard medical-device precautions:
-
Contraindicated in patients with known hypersensitivity to hyaluronic acid, lidocaine, or any formulation component
-
Contraindicated in the presence of active skin infection or inflammation at the injection site
-
Not intended for use in pregnant or breastfeeding patients (precautionary)
-
For intravascular injection avoidance, standard clinical precautions apply
Regulatory Status
-
CE-marked medical device (Class III, dermal filler)
-
UKCA status: verify via IFU or authorised UK distributor
Regulatory classification not fully specified in public documentation; verify on the product pack or manufacturer’s IFU.
FAQ
What type of dermal filler is Teosyal® RHA 3?
Teosyal® RHA 3 is a resorbable dermal filler composed of cross-linked hyaluronic acid produced using Teoxane’s RHA® technology. It is designed to adapt to facial movement while maintaining structural integrity in dynamic areas. The formulation includes lidocaine to enhance comfort during injection.
How does RHA® technology differ from standard HA fillers?
RHA® technology modifies the cross-linking process to preserve longer HA chains, supporting elasticity and resilience during repeated facial movement. This contrasts with traditional fillers that may prioritise rigidity or projection over flexibility.
Does Teosyal® RHA 3 contain lidocaine?
Yes. Teosyal® RHA 3 contains lidocaine hydrochloride to reduce discomfort during administration. The exact concentration is not specified in publicly available manufacturer documents .
How long do results last?
The manufacturer does not specify an exact longevity duration in the IFU. Persistence of effect varies depending on patient metabolism, treatment area, and technique, and should be discussed within a clinical consultation context .
Is Teosyal® RHA 3 interchangeable with other fillers?
No. While it may be compared for orientation with other dynamic-area fillers, Teosyal® RHA 3 has specific rheological properties and indications. Products are not interchangeable without clinical assessment and training .
